HPV16-targeted immunotherapy (Hookipa Biotech)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for HPV16-targeted immunotherapy (Hookipa Biotech), covering 2025-09-15 to 2025-09-15. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers [Phase 1, Phase 2]